Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
2017 ◽
Vol 28
(6)
◽
pp. 492-499
◽
Keyword(s):
Phase 3
◽
Keyword(s):